Amicus Therapeutics Provides Full-Year 2013 Financial Guidance and Strategic Outlook

Amicus Therapeutics Provides Full-Year 2013 Financial Guidance and Strategic
Outlook

6-Month (Stage 1) Results from Ongoing Phase 3 Fabry Disease Monotherapy Study
 at Lysosomal Storage Disease Network WORLD Symposium (LDN WORLD) in February
                   2013; 12-Month Results Expected in 2Q13

Pompe, Fabry and Other New Chaperone-Enzyme Replacement Therapy (ERT) Programs
                              Advancing in 2013

 FY13 Cash Spend Guidance Range of $52-$58 Million — Current Cash Expected to
                      Fund Operations into at Least 2H14

CRANBURY, N.J., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing
therapies for rare and orphan diseases, today provided its full-year 2013
strategic outlook and financial guidance. John F. Crowley, Chairman and CEO of
Amicus, will discuss Amicus' corporate objectives and key milestones in a
presentation at the 31st Annual J.P. Morgan Healthcare Conference on
Wednesday, January 9, 2013 at 3 p.m. PT (6 p.m. ET). A live webcast of the
presentation can be accessed through the Investors section of the Amicus
Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.

Mr. Crowley stated, "We have a great 2013 ahead of us. The Stage 1 data from
our Fabry monotherapy Study 011 are certainly encouraging. We look forward to
presenting additional detail about this 6-month data from Study 011 at the
WORLD Symposium in February. We also look forward to receiving and analyzing
the 12-month efficacy and safety data from Stage 2 of Study 011 in the second
quarter of this year. With these data, we expect to engage in constructive
discussions with the FDA regarding a U.S. approval pathway for migalastat HCl
as the first orally available pharmacological chaperone monotherapy for Fabry
disease. Additionally, our Pompe program continues to provide excellent data
demonstrating positive effects of AT2220-ERT co-administration, especially
regarding the potential to mitigate the immune response to ERT as shown in
preclinical studies. Finally, we continue to advance our chaperone-ERT
co-formulated products. We believe that these next-generation ERTs have the
potential to transform the treatment paradigm for many lysosomal storage
diseases."

2013 Financial Guidance

Cash, cash equivalents, and marketable securities totaled $99.1 million at
December 31, 2012 compared to $55.7 million at December 31, 2011. Amicus
expects full-year 2013 net cash spend between $52 million and $58 million. The
current cash position and anticipated Fabry program reimbursements from GSK
are projected to fund operations into the second half of 2014.

Amicus and GSK are co-developing all formulations of migalastat HCl under a
global Fabry collaboration. Amicus has commercial rights to all Fabry products
in the United States and GSK has commercial rights to all of these products in
the rest of world. Amicus and GSK are responsible for 40% and 60% of global
development costs, respectively, in 2013 and beyond. Outside the GSK
collaboration, Amicus owns exclusive rights to the rest of its pipeline and
applications of its platform technology.

Strategic Outlook

Amicus is leveraging its pharmacological chaperone technology platform to
develop next-generation medicines for a range of rare and orphan diseases,
with a focus on improved therapies for lysosomal storage disorders. During
2013, Amicus and GSK are committed to advancing migalastat HCl for Fabry
disease. Amicus will also continue to advance its pharmacologic chaperone
technology platform to develop next-generation therapies (ERTs) for Pompe and
additional lysosomal storage disorders. These programs include novel small
molecules co-administered with existing enzyme replacement products, as well
as proprietary next-generation enzyme replacement therapies that are
co-formulated with pharmacologic chaperones.

Migalastat HCl Monotherapy for Fabry Disease

Migalastat HCl monotherapy (150 mg, every-other-day (QOD)) is in two
randomized ongoing Phase 3 studies for Fabry Disease (Study 011 and Study 012)
in patients with genetic mutations identified as amenable to this
pharmacologic chaperone in a cell-based assay.

  *Study 011 is comparing migalastat HCl to placebo to potentially support a
    U.S. marketing application. In December 2012, Amicus and GSK announced
    encouraging top-line Stage 1 results from the 6-month double-blind
    treatment period in Study 011 (Stage 1). Additional 6-month data will be
    presented at the Lysosomal Disease Network WORLD Symposium (LDN WORLD), to
    be held February 12-15, 2013, in Orlando, Florida. Data from the 6-month
    open-label follow up period in Study 011 (Stage 2) in which all patients
    received migalastat HCl are anticipated in the first half of 2013. These
    results will include 12 months of data for the migalastat HCl group and 6
    months of data for the group that crossed over from placebo to migalastat
    HCl. The FDA has indicated that it will consider the entirety of the
    efficacy and safety data from Stage 1 and Stage 2 of Study 011. Amicus and
    GSK expect to meet with the FDA in 2013 to discuss a U.S. approval pathway
    for migalastat HCl monotherapy.
    
  *Study 012 is comparing open-label migalastat HCl to current standard of
    care ERTs (Fabrazyme and Replagal) to support global registration. In
    December 2012, this study achieved full enrollment of 60 patients, who
    were randomized 1.5:1 to switch from ERT to migalastat HCl or remain on
    ERT. Data is anticipated in the second half of 2014 on the primary outcome
    measure, which is renal function assessed by iohexol Glomerular Filtration
    Rate (GFR) at 18 months.

Chaperone-ERT Co-Administration

AT2220 Co-Administered with Marketed ERTs for Pompe Disease

In January 2013, Amicus announced positive results from all four patient
cohorts in a Phase 2 study (Study 010) to evaluate the safety and
pharmacokinetic (PK) effects of the pharmacological chaperone AT2220
co-administered with the standard of care ERTs for Pompe disease
(Myozyme^®/Lumizyme^®, or recombinant GAA enzymes). Results from this study
established human proof-of-concept that AT2220-ERT co-administration increases
GAA enzyme activity in muscle, particularly at the fourth and highest dose
cohort of AT2220 (600 mg). Based on these results, Amicus plans to conduct a
repeat-dose clinical study to investigate the effect of AT2220-ERT
co-administration on ERT stability and activity, ERT-related immunogenicity,
and other clinical measures. This study is expected to begin in the third
quarter of 2013.

By stabilizing the folded and active form of the infused GAA enzyme, AT2220
may also mitigate ERT-induced immunogenicity since unfolded and aggregated
proteins are generally more antigenic than properly folded proteins. Initial
ex vivo studies using T cells derived from blood from 50 healthy donors
demonstrated that the addition of AT2220 may significantly reduce the
immunogenicity of Myozyme and Lumizyme. The studies utilized Antitope Ltd.'s
EpiScreen™ assay and are being repeated in samples from the Pompe patients in
Study 010. Results from Study 010 will be presented during LDN WORLD.
Additional details regarding the Amicus Pompe program will be provided during
the presentation and live webcast at the JPMorgan conference.

Migalastat HCl Co-Administered with Marketed ERTs for Fabry Disease

When co-administered with ERT, migalastat HCl is designed to bind to and
stabilize infused enzyme in the circulation in any patient receiving ERT for
Fabry disease. Amicus and GSK have completed an open-label Phase 2 study
(Study 013) to investigate the effects of a single oral dose of migalastat HCl
(150 mg or 450 mg) co-administered prior to ERT (Fabrazyme or Replagal) in 23
males with Fabry disease. Positive preliminary results were announced during
2012 in patients who received migalastat HCl 150 mg co-administered with ERT.
Results for migalastat HCl 450 mg co-administered with ERT will be presented
at LDN WORLD.

Chaperone-ERT Co-Formulation

Migalastat HCl Co-Formulated with Proprietary ERT for Fabry Disease

Migalastat HCl co-formulated with JCR Pharmaceutical Co. Ltd's proprietary
investigational ERT (JR-051, recombinant human alpha-Gal A enzyme) is in
preclinical development. Amicus and GSK, in collaboration with JCR, are
currently conducting preclinical formulation and IND-enabling studies of this
chaperone-ERT co-formulated product, which has the potential to enter the
clinic in late-2013 or early 2014. 

AT2220 Co-Formulated with Amicus Proprietary Next-Generation ERT

Amicus is combining its core pharmacological chaperone technology with
advanced biologics capabilities to create a next-generation Pompe ERT. The
Company is designing this co-formulated chaperone-ERT product with the goal of
increasing exposure and tissue uptake and reducing immunogenicity of current
ERTs. The co-formulation with AT2220 may also allow the ERT to be administered
through novel routes. Amicus has entered into a contract with Laureate
Pharmaceuticals for the contract manufacture of this next-generation ERT.
Additional details regarding this aspect of the Amicus Pompe program will also
be provided during the presentation and live webcast at the JPMorgan
conference.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of developing therapies for rare and orphan diseases. The Company is
developing orally-administered, small molecule drugs called pharmacological
chaperones, a novel, first-in-class approach to treating a broad range of
human genetic diseases. Amicus' late-stage programs for lysosomal storage
disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease;
migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase
2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe
disease.

About Migalastat HCl for Fabry Disease

Amicus in collaboration with GlaxoSmithKline (GSK) is developing the
investigational pharmacological chaperone migalastat HCl for the treatment of
Fabry disease. Amicus has commercial rights to all Fabry products in the
United States and GSK has commercial rights to all of these products in the
rest of world. As a monotherapy, migalastat HCl is designed to bind to and
stabilize, or "chaperone" alpha-galactosidase A (alpha-Gal A) enzyme in
patients with genetic mutations that are amenable to this chaperone in a
cell-based assay. For patients currently receiving ERT for Fabry disease,
migalastat HCl in combination with ERT may improve ERT outcomes by keeping the
infused alpha-Gal A enzyme in its properly folded and active form.

Fabry disease is an inherited lysosomal storage disease that is currently
estimated to affect approximately 5,000 to 10,000 people worldwide. Fabry
Disease is caused by deficiency of an enzyme called alpha-galactosidase A
(alpha-Gal A). The role of alpha-Gal A within the body is to break down a
complex lipid called globotriaosylceramide (GL-3). Reduced or absent levels of
alpha-Gal A activity leads to the accumulation of GL-3 in the affected
tissues, including the central nervous system, heart, kidneys, and skin. This
accumulation of GL-3 is believed to cause the various symptoms of Fabry
disease, including pain, kidney failure, and increased risk of heart disorders
and stroke.

About AT2220 for Pompe Disease

AT2220 is an investigational, orally-administered pharmacological chaperone
owned exclusively by Amicus. In published preclinical studies, AT2220-ERT
co-administration resulted in significant increases in muscle rhGAA levels and
decreases in glycogen levels in a mouse model of Pompe disease. Preclinical
results to date also suggest that AT2220-ERT co-administration may mitigate
ERT-induced immunogenicity by stabilizing the enzyme in its properly folded
and active form.

Pompe disease is a lysosomal storage disease characterized by progressive
skeletal muscle weakness and respiratory insufficiency. It is caused by a
deficiency in GAA activity, which leads to accumulation of glycogen in tissues
affected by the disease (primarily muscle). Pompe disease affects an estimated
5,000 to 10,000 individuals worldwide and is clinically heterogeneous in the
age of onset, the extent of organ involvement, and the rate of progression.

Forward-Looking Statements

This press release contains, and the accompanying conference call will
contain, "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 relating to preclinical and clinical
development of Amicus' candidate drug products, the timing and reporting of
results from preclinical studies and clinical trials evaluating Amicus'
candidate drug products, and the projected cash position for the Company.
Words such as, but not limited to, "look forward to," "believe," "expect,"
"anticipate," "estimate," "intend," "plan," "targets," "likely," "will,"
"would," "should" and "could," and similar expressions or words identify
forward-looking statements. Such forward-looking statements are based upon
current expectations that involve risks, changes in circumstances, assumptions
and uncertainties. The inclusion of forward-looking statements should not be
regarded as a representation by Amicus that any of its plans will be achieved.
Any or all of the forward-looking statements in this press release may turn
out to be wrong. They can be affected by inaccurate assumptions Amicus might
make or by known or unknown risks and uncertainties. For example, with respect
to statements regarding the goals, progress, timing and outcomes of
discussions with regulatory authorities and the potential goals, progress,
timing and results of preclinical studies and clinical trials, actual results
may differ materially from those set forth in this release due to the risks
and uncertainties inherent in the business of Amicus, including, without
limitation: the potential that results of clinical or pre-clinical studies
indicate that the product candidates are unsafe or ineffective; the potential
that it may be difficult to enroll patients in our clinical trials; the
potential that regulatory authorities may not grant or may delay approval for
our product candidates; the potential that preclinical and clinical studies
could be delayed because we identify serious side effects or other safety
issues; the potential that we will need additional funding to complete all of
our studies and, our dependence on third parties in the conduct of our
clinical studies. Further, the results of earlier preclinical studies and/or
clinical trials may not be predictive of future results. With respect to
statements regarding projections of the Company's cash position, actual
results may differ based on market factors and the Company's ability to
execute its operational and budget plans. In addition, all forward looking
statements are subject to other risks detailed in our Quarterly Report on Form
10-Q for the quarter ended June 30, 2012. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement, and Amicus undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date hereof.
This caution is made under the safe harbor provisions of Section21E of the
Private Securities Litigation Reform Act of 1995.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044
 
Press spacebar to pause and continue. Press esc to stop.